Healthcare systems have had to adapt to evolving challenges in recent years, and in response, the pharmaceutical and biotechnology sectors have implemented different innovative pricing and reimbursement models. In an article for MedTech Strategist, we explore whether similar innovative reimbursement and contracting schemes might be developed for medical technologies and how the challenges they bring might be overcome.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...